View by Specialty

Trending

AdobeStock_Carrots_1200x630
November 18, 2024
1 min read
Save

CDC: 1 dead in multistate outbreak of E. coli linked to organic carrots

Gastroenterology News

SPONSORED CONTENT
Save
SPONSORED CONTENT
June 05, 2024
2 min read
Save

GLP-1 receptor agonists ‘have changed the playing field’ in pediatric MASLD

GLP-1 receptor agonists ‘have changed the playing field’ in pediatric MASLD

WASHINGTON — Glucagon-like peptide-1 receptor agonists significantly reduced alanine aminotransferase levels in pediatric metabolic dysfunction-associated steatotic liver disease, especially those with type 2 diabetes, researchers reported.

SPONSORED CONTENT
June 05, 2024
1 min read
Save

Recalled cucumbers may be cause of ongoing Salmonella outbreak

Recalled cucumbers may be cause of ongoing <i>Salmonella</i> outbreak

The CDC on Wednesday announced that recalled cucumbers have been identified as the potential cause of an ongoing Salmonella outbreak.

Trending

AdobeStock_Carrots_1200x630
November 18, 2024
1 min read
Save

CDC: 1 dead in multistate outbreak of E. coli linked to organic carrots

SPONSORED CONTENT
June 05, 2024
3 min read
Save

A 100% response rate suggests dostarlimab is ‘definitive’ therapy for rectal cancer

A 100% response rate suggests dostarlimab is &lsquo;definitive&rsquo; therapy for rectal cancer

CHICAGO — A phase 2 study evaluating dostarlimab in adults with mismatch repair-deficient locally advanced rectal cancer has maintained a 100% clinical complete response rate at a median follow-up of almost 18 months.

SPONSORED CONTENT
June 05, 2024
3 min read
Save

‘Promise of lasting efficacy’: Guselkumab outperforms placebo, ustekinumab in Crohn’s

&lsquo;Promise of lasting efficacy&rsquo;: Guselkumab outperforms placebo, ustekinumab in Crohn&rsquo;s

WASHINGTON — In patients with active Crohn’s disease, guselkumab was superior to both placebo and standard-of-care ustekinumab after 48 weeks of treatment, according to late-breaking data from the phase 3 GALAXI program.

SPONSORED CONTENT
June 05, 2024
1 min watch
Save

VIDEO: Results from SEQUENCE trial ‘important’ for treatment selection in Crohn’s

VIDEO: Results from SEQUENCE trial &lsquo;important&rsquo; for treatment selection in Crohn&rsquo;s

In this Healio video, Uma Mahadevan, MD, director of the Colitis and Crohn’s Disease Center at the University of California, San Francisco, recaps results from the SEQUENCE trial, which were presented at Digestive Disease Week 2024.

SPONSORED CONTENT
June 04, 2024
3 min watch
Save

VIDEO: Lifestyle modifications must be ‘personalized to the patient’ in GERD management

VIDEO: Lifestyle modifications must be &lsquo;personalized to the patient&rsquo; in GERD management

WASHINGTON — In a Healio video exclusive, Carolyn Newberry, MD, discusses the importance of “personalized” lifestyle modifications, such as identifying dietary triggers and being mindful of meal-timing, for the management of GERD.

SPONSORED CONTENT
June 04, 2024
2 min read
Save

CDC: Hepatitis C clearance rates well below national elimination goals

CDC: Hepatitis C clearance rates well below national elimination goals

Hepatitis C virus clearance rates in all states fell well short of national elimination goals, a study published in MMWR showed.

SPONSORED CONTENT
June 04, 2024
2 min read
Save

Evolocumab shows particular CV benefit in those with autoimmune disease, inflammation

Evolocumab shows particular CV benefit in those with autoimmune disease, inflammation

Patients with atherosclerosis and elevated LDL plus autoimmune or inflammatory disease may derive particular CV benefit from PCSK9 inhibition with evolocumab, a speaker reported.

SPONSORED CONTENT
June 04, 2024
5 min watch
Save

VIDEO: ‘Compelling data’ from VIVID-1 study support use of mirikizumab in Crohn’s disease

VIDEO: &lsquo;Compelling data&rsquo; from VIVID-1 study support use of mirikizumab in Crohn&rsquo;s disease

WASHINGTON — In this video, Mark Genovese, MD, discusses results of the VIVID-1 study, in which mirikizumab demonstrated noninferiority to ustekinumab for week 52 clinical remission among patients with moderate to severe Crohn’s disease.

SPONSORED CONTENT
June 03, 2024
2 min read
Save

A catered low-fat, high-fiber diet ‘new, hopeful option’ to manage Crohn’s disease

A catered low-fat, high-fiber diet &lsquo;new, hopeful option&rsquo; to manage Crohn&rsquo;s disease

WASHINGTON — Patients with Crohn’s disease who ate a catered low-fat, high-fiber diet for 8 weeks experienced improvements in symptoms, inflammation and quality of life vs. those offered counseling alone, researchers reported.

View more
Healio Minute Subscribe to Healio Minute emails You're now subscribed to Healio Minute Emails
Healio Minute Subscribe to Healio Minute emails You're now subscribed to Healio Minute Emails